Novartis Financial Results – Q2 2026
Novartis announces the company’s financial results for the second quarter and first half of 2026.
Latest news
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Small shifts. Big impact. The leadership choices that matter most in the age of AI
30 years of Novartis, powered by 250 years of innovation
Rooted in a legacy of scientific discovery, Novartis continues to advance breakthrough medicines that redefine the future of care for patients.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.